Discovery and Design of Novel Vasopresses Hypotensive Pepitide Agonists

Journal of Receptor and Signal Transduction Research

Volumn 19, Issue 42008, 1999, Pages 631-644

  Manning, M ^a   Stoev, S ^a   Cheng, L L ^a   wo, N C ^b   Chan, W Y ^b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ARGIPRESSIN DERIVATIVE; OXYTOCIN; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

AMINO ACID SUBSTITUTION; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; CONFERENCE PAPER; DOSE RESPONSE; DRUG DESIGN; DRUG ISOLATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

AFFINITY LABELS; AMINO ACID SEQUENCE; ANIMALS; ANTIHYPERTENSIVE AGENTS; ARGININE VASOPRESSIN; DRUG DESIGN; FEMALE; RATS; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN; STRUCTURE-ACTIVITY RELATIONSHIP; VASOPRESSINS;

EID: 0033062563     PISSN: 10799893     EISSN: None     Source Type: Journal    
DOI: 10.3109/10799899909036676     Document Type: Article

References (23)

1. Manning M., Cheng L. L., Klis W. A., Stoev S., Przybylski J., Bankowski K., Sawyer W. H., Barberis C., Chan W. Y. Advances in the design of selective antagonists, potential tocolytics and radioiodinated ligands for oxytocin receptors. Oxytocin: Cellular and Molecular Approaches in Medicine and Research, R. Ivell, J. Russel. Plenum Press, New York 1995; 559 – 583
2. Manning M., Cheng L. L., Stoev S., Sawyer W. H., Tribollet E., Barberis C., Wo N. C., Chan W. Y. Novel potent and selective antagonists and radioiodinated ligands for oxytocin and vasopressin receptors. Neurohypophisis: Recent Progress of Vasopressin and Oxytocin Research, T. Saito, K. Kurokawa, S. Yoshido. Elsevier Science B. V., Amsterdam 1995; 21 – 38
3. Manning M., Olma A., Klis W. A., Kolodziejczyk A. M., Seto J., Sawyer W. H. Design of more potent antagonists of the antidiuretic responses to arginine vasopressin. J. Med. Chem. 1982; 25: 45 – 50
4. Manning M., Cheng L. L., Stoev S., Bankowski K., Przybylski J., Klis W. A., Sawyer W. H., Wo N. C., Chan W. Y. An exploration of the effects of L- and D-Tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin. J. Peptide Sci. 1995; 1: 66 – 79
5. Manning M., Cheng L. L., Stoev S., Klis W. A., Nawrocka E., Olma A., Sawyer W. H., Wo N. C., Chan W. Y. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists. J. Peptide Sci. 1997; 3: 31 – 46
6. Manning M., Stoev S., Wo N. C., Chan W. Y. Discovery of novel selective hypotensive analogues of a vasopressin antagonist. Peptides, 1996, R. Ramage, R. Epton. Mayflower Scientific Ltd., England 1998; 615 – 616
7. Chan W. Y., Wo N. C., Stoev S., Cheng L. L., Manning M. Discovery of novel selective hypotensive vasopressin peptides: A new vasodilating vasopressin receptor?. Vasopressin and Oxytocin: Synopsis of Recent Advances in Molecular, Cellular and Clinical Research, H. H. Zingg, D. G. Bichet, C. Bourque. Plenum Press, New York, in press
8. Share L. Role of vasopressin in cardiovascular regulation. Physiological Reviews 1988; 68: 1248 – 1284
9. Elands J., Barberis C., Jard S., Tribollet E., Dreifuss J. J., Bankowski K., Manning M., Sawyer W. H. 125I-labelled d(CH2)5[Tyr(Me)2,Tyr-NH2 9]OVT: A selective oxytocin receptor ligand. Eur. J. Pharmacol. 1988; 147: 197 – 207
10. Schmidt A., Audiger S., Barberis C., Jard S., Manning M., Kolodziejczyk A. S., Sawyer W. H. A radioiodinated linear vasopressin antagonist: A ligand with high affinity and specificity for V1a receptors. FEBS Lett. 1991; 282: 77 – 81
11. Barberis C., Balestre M.-N., Jard S., Tribollet E., Arsenijevic Y., Dreifuss J. J., Bankowski K., Manning M., Chan W. Y., Schlosser S. S., Holsboer F., Elands J. Characterization of a novel, linear radio-iodinated vasopressin antagonist:An excellent radioligand for vasopressin V1a receptors. Neuroendocrinology 1995; 62: 135 – 146
12. Ala Y., Morin D., Mahe E., Cotte N., Mouillac B., Jard S., Barberis C., Tribollet E., Dreifuss J. J., Sawyer W. H., Wo N. C., Chan W. Y., Kolodziejczyk A. S., Cheng L. L., Manning M. Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptors. Eur. J. Pharmacol. 1997; 331: 285 – 293
13. Manning M., Klis W. A., Kruszynski M., Przybylski J. P., Olma A., Wo N. C., Pelton G. H., Sawyer W. H. Novel linear antagonists of the vasopressor (V1) and antidiuretic (V2) responses to vasopressin. Int. J. Pept. Protein Res. 1988; 32: 455 – 467
14. Sawyer W. H., Bankowski K., Misicka A., Nawrocka E., Kruszynski M., Stoev S., Klis W. A., Przybylski J. P., Manning M. Potent V2 vasopressin antagonists with structural changes at their C-terminals. Peptides 1988; 9: 157 – 163
15. Kruszynski M., Lammek B., Manning M., Seto J., Haldar J., Sawyer W. H. [1-(β-Mercapto-β,β-cyclopentamethylenepropionic acid), 2-(O-methyl) tyrosine] arginine-vasopressin and [1-(β-Mercapto-β,β-cyclopentamethylenepropionic acid)] arginine-vasopressin, two highly potent antagonists of the vasopressor response to arginine-vasopressin. J. Med. Chem. 1980; 23: 364 – 368
16. Holton P. A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract. Br. J. Pharmacol. 1948; 23: 328 – 334
17. Schild H. O. PA, a new scale of the measurement of drug antagonism. Br. J. Pharmacol. Chemother. 1947; 2: 189 – 206
18. Dykes D. F., Nestor J. J., Jr., Ferger M. F., du Vigneaud V. [1-β-Mercapto-β,β-diethylpropionic acid]-8-lysine-vasopressin, a potent inhibitor of 8-lysine-vasopressin and oxytocin. J. Med. Chem. 1974; 17: 250 – 252
19. Sawyer W. H. Biologic assays for oxytocin and vasopressin. Methods Med. Res. 1961; 9: 210 – 219
20. Dekanski J. The quantitative assay of vasopressin. Br. J. Pharmacol. 1952; 7: 567 – 572
21. Munsick R. A. Effect of magnesium ion on the response of the rat uterus to neurohypophysial hormones and analogues. Endocrinology 1960; 66: 451 – 457
22. Merrifield R. B. Solid-phase peptide synthesis. III. An improved synthesis of Bradykinin. Biochemistry 1964; 3: 1385 – 1390
23. Stewart J. M., Young J. D. Solid Phase Peptide SynthesisSecond Edition. Pierce Chemical Company, Rockford, IL 1984